EUCTR2012-004482-40-ES
Active, not recruiting
Not Applicable
Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis (RA) in persistent clinical remission in treatment with biological therapies: open, controlled study and randomized.
FRANCISCO J. BLANCO GARCÍA0 sitesMay 16, 2013
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis in clinical remission at treatment with biologic therapies
- Sponsor
- FRANCISCO J. BLANCO GARCÍA
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •? Patients over 18 years.
- •? Patients with rheumatoid arthritis (RA) according to the classification of the 1987 ACR criteria.
- •? Patients treated with biologic therapy (infliximab, adalimumab, etanercept, golimumab, certolizumab, abatacept, rituximab, tocilizumab) showing an established clinical remission.
- •? Patients who are in remission (defined by a DAS28 \<2\.4 or SDAI \<3\.3\) during the last 6 months prior the baseline visit.
- •? Patients who give their informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 1200
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •? Patients with RA and clinic predominantly systemic manifestations to which biological therapy on the occasion of such systemic manifestations have been instructed.
- •? Patients with AR and any associated pathology known that interfere with or modify the clinical evaluation of the patient (fibromyalgia or association to another chronic inflammatory disease).
- •? Patients in chronic treatment with biologic therapy that are already in some patterns of reduction which will be studied in the experimental group, or guidelines of dose lower or more spaced than the of the experimental group, prior to inclusion in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of Krishnavajrabhraka Bhasma [KVB] in AsthmaHealth Condition 1: null- Chronic bronchial AsthmaCTRI/2018/04/013084Department of Indian System of Medicine Homoepathy AYUSH41
Completed
Not Applicable
The utility of standardised pre-clinical assessment based on the Development And Well-Being Assessment (DAWBA) in a child and adolescent mental health serviceChildhood psychiatric disordersMental and Behavioural DisordersISRCTN19935149niversity of Zurich (Switzerland)500
Not yet recruiting
Phase 1
Standardized research and clinical efficacy evaluation of treatment of interstitial lung disease based on lung-collateral theoryinterstitial lung diseaseITMCTR2000003785Shanghai Pulmonary Hospital
Not yet recruiting
Not Applicable
Clinical study of standardized Ashwagandha in healthy male volunteersCTRI/2023/04/051632Pharmanza Herbal Pvt. Ltd.
Active, not recruiting
Not Applicable
Evaluation of clinical value of a standardized protocol for dose reduction in patients with axial Spondyloarthritis and clinical remission with anti-TNF therapyEUCTR2011-005871-18-ESCLINICAL PHARMACOLOGY SPANISH SOCIETY